BioForce Nanosciences (BFNH) Stock Price, News & Analysis

Company Overview

BioForce Nanosciences, Inc. develops and markets precision instrumentation and proprietary technologies for the production and application of nanoscale materials. Its core platform employs nozzle-driven electrohydrodynamic processes to generate and deposit nanofibers, nanowires and nanoparticles with tight control over diameter, morphology and spatial arrangement. By tailoring electric field parameters and solution properties, the technology enables reproducible fabrication of structures at the nanometer scale.

The company’s product portfolio includes desktop electrospinning systems for nanofiber fabrication, electrospray modules for nanoparticle synthesis and integrated tools for bioprinting and surface patterning. In addition to equipment sales, BioForce Nanosciences offers contract research and custom development services, as well as licensing agreements for its intellectual property. Its technologies have been applied in areas such as drug delivery, tissue engineering, advanced filtration, composite materials and sensor development.

Serving academic institutions, government laboratories and corporate research centers, BioForce Nanosciences supports customers worldwide with training, application development and technical service. By combining instrumentation, service offerings and technology licensing, the company aims to accelerate the translation of nanomaterial innovations into practical solutions for life science, industrial and environmental applications.

Key Stats

• Today's Range: $0.41 to $0.81
• 50-Day Range: $0.52 to $0.88
• 52-Week Range: $0.33 to $1.10
• Volume: 7,724 shs
• Average Volume: 910 shs
• Market Capitalization: $27.19 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BioForce Nanosciences Stock Analysis - MarketRank™

BioForce Nanosciences scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for BioForce Nanosciences.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BioForce Nanosciences is -20.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioForce Nanosciences is -20.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of BioForce Nanosciences has been sold short.

Short Interest Ratio / Days to Cover

BioForce Nanosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioForce Nanosciences does not currently pay a dividend.

Dividend Growth

BioForce Nanosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the float of BioForce Nanosciences has been sold short.

Short Interest Ratio / Days to Cover

BioForce Nanosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for BFNH on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioForce Nanosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

39.54% of the stock of BioForce Nanosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

BFNH Stock Analysis - Frequently Asked Questions

How have BFNH shares performed this year?

BioForce Nanosciences' stock was trading at $0.3415 at the beginning of the year. Since then, BFNH shares have increased by 137.5% and is now trading at $0.8111.

How were BioForce Nanosciences' earnings last quarter?

BioForce Nanosciences Holdings Inc. (OTCMKTS:BFNH) posted its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.03) earnings per share (EPS) for the quarter.

How do I buy shares of BioForce Nanosciences?

Shares of BFNH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioForce Nanosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioForce Nanosciences investors own include Nano One Materials (NANO) and Charlotte's Web (CWBHF).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 10/11/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: OTCMKTS:BFNH
• CIK: 1310488
• Web: www.bioforceeclipse.com
• Phone: (757) 306-6090
• Fax: 757-306-6092
• Employees: 2
• Year Founded: 2003

Profitability

• EPS (Trailing Twelve Months): ($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$490 thousand
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -30,300.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.07) per share
• Price / Book: -11.59

Miscellaneous

• Outstanding Shares: 33,520,000
• Free Float: 20,267,000
• Market Cap: $27.19 million
• Optionable: Not Optionable
• Beta: -0.76